Bio-Rad Laboratories, Inc. (BUW.F)
| Previous Close | 312.00 |
| Open | 312.00 |
| Bid | 264.00 x N/A |
| Ask | 274.00 x N/A |
| Day's Range | 312.00 - 312.00 |
| 52 Week Range | 288.00 - 450.00 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 7.356B |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -20.37 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif., May 01, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).
ZacksAnalysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireBio-Rad Announces Life Science Group Management Changes
HERCULES, Calif., April 26, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024. He succeeds Dr. Simon May, who has announced his decision to leave the company to pursue another professional opportunity.
